Metabotropic glutamate receptor type 1 (mGluR1) is thought to play important roles in the neurotransmission and pathogenesis of several neurological disorders. Here, we describe the radioligand binding properties and pharmacological effects of a newly synthesized, high-affinity, selective, and noncompetitive mGluR1 antagonist, 6-amino-N-cyclohexyl-N,3-dimethylthiazolo[3,2-a] for mGluR1 over mGluR subtypes 2 to 7, ionotropic glutamate receptors, and other receptor, transporter, and ion channel targets. In in vivo experiments, orally administered YM-298198 showed a significant analgesic effect in streptozotocin-induced hyperalgesic mice at doses (30 mg/kg) that did not cause Rotarod performance impairment, indicating that it is also useful even for in vivo experiments. In conclusion, YM-298198 is a newly synthesized, high-affinity, selective, and noncompetitive antagonist of mGluR1 that will be a useful pharmacological tool due to its highly active properties in vitro and in vivo. Its radiolabeled form [ 3 H]YM-298198 will also be a valuable tool for future investigation of the mGluR1.
(I-III). Among these, mGluR1, cloned in 1991 (Masu et al., 1991) and attributed to group I, is coupled to Ca 2ϩ /inositol triphosphate signal transduction and is expressed in many central nervous system regions, especially the cerebral cortex, hippocampus, thalamus, and cerebellum (Martin et al., 1992) . Studies of mGluR1 nucleic acid sequence manipulation suggested that they are involved in various pathophysiological conditions. Mutant mice lacking mGluR1 show characteristic cerebellar symptoms such as ataxic gait and intention tremor (Aiba et al., 1994; Conquet et al., 1994) and an increase of the nociceptive threshold (Corsi et al., 1996) . Additionally, intrathecal administration of mGluR1 antisense oligonucleotides shows an analgesic effect in rat formalin tests, complete Freund's adjuvant-treated rats, and nerve-injured rats (Fundytus et al., 2001 (Fundytus et al., , 2002 Noda et al., 2003) . Antisense oligonucleotides also markedly reduce sustained excitatory responses to mustard oil in multireceptive dorsal horn neurons in rats (Young et al., 1998) . Although these results support claims of pivotal roles of mGluR1 in pathophysiological conditions, including chronic pain states, the lack of mGluR1 antagonists highly active in vitro and in vivo limited the investigation of the pathophysiological functions of mGluR1.
Recently, several mGluR1-specific antagonists have been discovered. 7-(Hydroxyimino)cyclo-propa [b] chromen-1a-carboxylate ethyl ester (CPCCOEt) is an antagonist that is structurally different from phenylglycines or glutamate (Litschig et al., 1999) . It inhibits receptor activity without affecting the binding affinity of glutamate, i.e., in a noncompetitive manner. BAY36-7620 and R214127 are more potent noncompetitive mGluR1 antagonists with inverse agonist activity (Carroll et al., 2001; Lavreysen et al., 2003) . Although intravenous administration of BAY36-7620 has been reported to protect neurons from degeneration in the acute subdural hematoma model, as well as to attenuate pentylenetetrazole-induced convulsions, the compound is not highly centrally active (De Vry et al., 2001; Lavreysen et al., 2004) . Thus, there remains a need for novel mGluR1 antagonists with higher affinity and better bioavailability for the future investigation of mGluR1s. In this context, YM-298198 was designed and synthesized as a novel mGluR1 antagonist. In the present study, radioligand binding properties and pharmacological profiles of YM-298198 were investigated through in vitro and in vivo experiments.
Materials and Methods
Materials. YM-298198 and YM-193167 (Fig. 1) [3,2-a] benzimidazole-2-carboxamide dihydrochloride 1.7 hydrate, a desmethyl derivative of YM-298198 (17.5 mg), was dissolved in 1 ml of N,N-dimethylformamide, and 7.5 mg of sodium hydride was added with stirring for 30 min at 0°C. The flask was then frozen in liquid nitrogen and evacuated to hard vacuum, and [
3 H]methyl iodide (5 Ci at 85 Ci/mmol) was distilled to it. The solution was allowed to thaw to room temperature and was stirred for 30 min. The reaction mixture was then partitioned between ethyl acetate and water, and the organic layer was collected. The aqueous layer was extracted with further portions of ethyl acetate, and the organic fractions were combined. A portion of the crude product, 250 mCi, was purified by high-performance liquid chromatography on an Ultrasphere ODS column eluting with a water/methanol/hydrochloric acid gradient system. The required product was collected, evaporated to dryness, and, after 2 ϫ 2 ml of ethanol was evaporated off to remove traces of hydrochloric acid, redissolved in ethanol. The highperformance liquid chromatography purification was repeated twice to obtain the required purity. The resulting [
3 H]YM-298198 had a radiochemical purity of 98.5% and a specific activity of 82 Ci/mmol. Animals. Male Wistar rats (Japan SLC, Hamamatsu, Japan) were used for preparation of cerebellum membrane fraction. Male ICR mice were purchased from Japan SLC for the nociceptive test and Rotarod performance assessment. They were given free access to solid food and water in an animal room maintained at 23 Ϯ 2C°and 55 Ϯ 10% humidity with a 13:11-h day/night cycle. All experiments were performed according to the regulations of the Animal Ethical Committee of Yamanouchi Pharmaceutical Co., Ltd.
Cell Culture and Membrane Preparation. NIH3T3 cells stably expressing rat mGlu1R␣ (mGluR1-NIH) and HEK293 cells stably expressing rat mGluR5a (mGluR5-HEK) were obtained as described previously (Kawabata et al., 1996) and cultured with Dulbecco's modified Eagle's medium with 10% dialyzed fetal bovine serum, 100 units/ml penicillin G, and 100 g/ml streptomycin. Chinese hamster ovary (CHO)-dhfr Ϫ cells stably expressing rat mGluR2, 3, 4a, 6, and 7b, received as gifts from S. Nakanishi (Kyoto University, Kyoto, Japan), were cultured with Dulbecco's modified Eagle's medium or ␣-minimum essential medium with 10% dialyzed fatal bovine serum, 1% L-proline, 100 units/ml penicillin G, and 100 g/ml streptomycin.
The cells cultured in 15-cm culture dishes were rinsed with Ca 2ϩ -and Mg 2ϩ -free Dulbecco's phosphate-buffered saline and removed from the dishes by scraping. The removed cells were homogenized with 2 mM HEPES, 10 mM EDTA, pH 7.4 (approximately 6 ml per dish) using a Polytron PTA 10-TS homogenizer (level 5, for 15 s, three times). The homogenate was centrifuged at 40,000g for 30 min at 4°C. The resulting pellet was resuspended with 2 mM HEPES, 10 mM EDTA, pH 7.4, and centrifuged at 40,000g for 30 min at 4°C. The final pellet was homogenized in 20 mM HEPES, 10 mM EDTA, pH 7.4, using a glass-Teflon homogenizer and stored in aliquots at Ϫ80°C until use. For the rat cerebellum membrane preparation, 11-to 12-week-old male Wistar rats were decapitated, and the cerebella were immediately dissected. The cerebella were homogenized with a Teflon-glass potter homogenizer in 10 volumes of 0.32 M sucrose and centrifuged at 900g for 15 min. After centrifugation, the resulting supernatant was further centrifuged at 15,000g for 20 min. The resulting pellet was washed twice by centrifugation at 15,000g for 20 min in 5 mM Tris-HCl, pH 7.4. The final pellet was homogenized in 50 mM Tris-HCl, pH 7.4, using a glass-Teflon homogenizer and stored in aliquots at Ϫ80°C until use.
IPs Accumulation Assay. Inositol phosphates (IPs) formation was measured according to the procedures described by Aramori and Nakanishi (1992) . Briefly, mGluR1-NIH cells were seeded on 24-well plates at a density of 1 ϫ 10 5 cells/well and cultured overnight in a CO 2 incubator (37°C, 5% CO 2 ). The wells were labeled with [
3 H]myoinositol (3 Ci/ml) and cultured overnight. The labeled cells were washed with PBS (137 mM NaCl, 2.68 mM KCl, 1.05 mM MgCl 2 , 0.9 mM CaCl 2 , 8.1 mM Na 2 HPO 4 , and 1.47 mM KH 2 PO 4 ) and incubated for 20 min at 37°C. The cells were further incubated with antagonists in PBS, including 10 mM LiCl (PBS-Li) for 20 min at 37°C. A reaction was started by exchanging the mixture with 10 mM LiCl in PBS including agonists/antagonists. After incubation (20 min at 37°C), the reaction was terminated by exchanging the reaction mixture with 1 ml of ice-cold 0.2 M perchloric acid. After standing (1-3 h at 4°C), 100 l of 2 N KOH and 50 l of 100 mM EDTA disodium salt were added into each well and mixed. One milliliter of reaction extract was added to AG1 ϫ 8 columns (Bio-Rad, Hercules, CA) and washed with 7 ml of wash solution (5 mM sodium tetraborate and 60 mM sodium formate). IPs were extracted by adding 4 ml of elution solution (0.1 M formate and 1 M ammonium formate), and the whole elutes were collected into liquid scintillation vials. The radioactivity of the elutes was counted using a liquid scintillation counter. EC 50 and IC 50 values were calculated from the nonlinear regression analysis using SAS version 8.2.
cAMP Accumulation Assay. Cyclic adenosine monophosphate (cAMP) accumulation was measured according to the procedures described by Tanabe et al. (1992) . Briefly, Chinese hamster ovary cells expressing rat mGluR2, 3, 4a, 6, and 7b were seeded at a density of 5 ϫ 10 4 cells/well on 24-well plates and cultured overnight in a CO 2 incubator (37°C, 5% CO 2 ). The wells were washed twice with PBS-3-isobutyl-1-methylxanthine (137 mM NaCl, 2.68 mM KCl, 1 mM MgCl 2 , 0.85 mM CaCl 2 , 8.1 mM Na 2 HPO 4 , 1.47 mM KH 2 PO 4 , and 1 mM isobutylmethylxantine) and incubated for 20 min at 37°C. After incubation, a reaction was started by adding a reaction mixture (PBS-3-isobutyl-1-methylxanthine including agonists/antagonists) and incubated for 10 min at 37°C. The reaction was terminated by exchanging the reaction mixture with 900 l of ice-cold 0.2 M percholic acid. After the mixture had stood for 1 to 3 h at 4°C, 100 l of 1.8 M KOH was added into the wells and mixed. The cyclic AMP level was determined using Biotrak cAMP EIA System (GE Healthcare).
Intracellular Ca 2؉ Mobilization. Intracellular Ca 2؉ mobilization was measured according to the procedures described by Kawabata et al. (1996) .
[ 3 H]YM-298198 Binding Assay. The binding assay was performed by the method of Thomsen et al. (1993) with minor modifications. Briefly, cell membranes or rat cerebellum membranes (20 -50 g of protein), [ 3 H]YM-298198, and competitors were incubated at 25°C for 30 min in 0.1 ml of 50 mM Tris-HCl, pH 7.4, containing 2.5 mM CaCl 2 . For the determination of nonspecific binding, 10 M YM-193167 was used. The incubation was terminated by rapid filtration through Whatman GF/B filters. Protein concentration was determined using Bio-Rad DC protein assay (Bio-Rad) in which bovine serum albumin was used as a standard. The specific binding was defined as a portion of the total binding, which was replaced by 10 M YM-193167. The dissociation constant (K D ) and binding site density (B max ) were calculated using Scatchard analysis using SAS version 8.2. The IC 50 values were calculated from the nonlinear regression analysis using SAS version 8.2. The values of the apparent equilibrium dissociation constant of inhibitors (K i ) were calculated by the method of Cheng and Prusoff (1973) .
[ 3 H]Quisqualate Binding Assay. The binding assay was performed by the method of Mutel et al. (2000) with minor modifications. Briefly, cell membranes (30 -50 g of protein), [ 3 H]quisqualate, and competitors were incubated at 25°C for 60 min in 0.1 ml of 50 mM Tris-HCl, pH 7.4, containing 2.5 mM CaCl 2 . For the determination of nonspecific binding, 1 mM glutamate was used. The incubation was terminated by rapid filtration through Whatman GF/B filters. The protein concentration was determined using BioRad DC protein assay (Bio-Rad) in which bovine serum albumin was used as a standard. The specific binding was defined as a portion of the total binding, which was replaced by 1 mM glutamate.
Specificity against Other Sites. The studies for the investigation of the affinity to ionotropic glutamate receptors, other known neurotransmitter receptors, ion channels, transporters, and enzymes were performed at NovaScreen (Hanover, MD), using published protocols.
Nociceptive Test. The tail-pinch test was conducted with a modification of the previously reported method (Takagi et al., 1966) . Briefly, the mice were tested by pinching their tail base with forceps (500g pressure), and nociceptive response latency (seconds) was measured with a cut-off time of 10 s to prevent tissue damage. The nociceptive response was indicated by biting of the forceps. An increase of the mechanical nociception was then induced by a modification of the previously reported method (Kamei et al., 1992) . Briefly, the mice were deprived of food but provided with water for about 18 h. They were then treated with single intraperitoneal administration of streptozotocin at 200 mg/kg body weight (approximately 20g at the streptozotocin administration). Streptozotocin was dissolved in citrate buffer solution adjusted to pH 4.5 and administered immediately. A control group of age-matched mice received administration of the vehicle. Two weeks after the streptozotocin or vehicle treatment, the mice treated with streptozotocin showed significantly shorter nociceptive response latency (median latency 1.85 s, Q1 1.15 and Q3 5.09 s, n ϭ 52) than mice treated with the vehicle (median latency 2.97 s, Q1 2.2 and Q3 7.88 s, n ϭ 42, p Ͻ 0.01 with Wilcoxon rank sum test), indicating that the mice treated with streptozotocin also showed increased mechanical nociception under our experimental conditions. Predrug response latency was measured on the 14th day after streptozotocin treatment, and the mice that showed latency shorter than 3 s were provided for the drug evaluation. The mice were allocated to three groups (14 mice per group) such that the differences in the averages of predrug nociceptive response latency among the groups were small. On the 15th day after streptozotocin treatment, postdrug response latency was measured 45 min after oral administration of YM-298198 at an administration volume of 10 ml/kg. The analgesic efficacy of the drugs was represented as prolongation of the nociceptive response latency, measured up to 10 s, obtained from individual scores and calculated according to the following formula: postdrug response latency Ϫ predrug response latency.
Rotarod Performance Assessment. Rotarod performance was assessed to evaluate the drug effect on motor coordination. The Rotarod apparatus (KN-75; Natsume Seisakusho, Tokyo, Japan) comprised a drum that rotated at a speed of 5 revolutions per min. Mice were placed individually on the rotating drum. The time in seconds at which each animal fell from the drum was recorded for up to 120 s using a stopwatch and indicated as performance time. Mice that show a 120-s performance time were selected for drug evaluation (n ϭ 8/group) by a predrug test session. In the drug evaluation session, Rotarod performance time was measured three times, up to
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Statistics. The competition study of CPCCOEt for [ 3 H]YM-298198 binding was statistically analyzed using a one-way analysis of variance followed by Dunnett's test. The results for analgesic effect in the nociceptive test and performance time in the Rotarod test were statistically analyzed using a nonparametric Kruskal-Wallis H test followed by Steel's test. Probability values less than 0.05 were considered significant.
Results
Antagonistic Activity at mGluR1-NIH Cells. YM-298198 inhibited glutamate-induced IP production with an IC 50 value of 16 Ϯ 5.8 nM (n ϭ 3; Fig. 2A ), whereas CPCCOEt inhibited it with an IC 50 value of 6.3 Ϯ 0.48 M. YM-298198 did not affect the basal IP production up to 10 M (data not shown). YM-298198 concentration dependently reduced the maximal IP production response to glutamate (Fig. 2, B and C) . YM-298198 also concentration dependently increased the EC 50 value of glutamate, whereas it did not affect the Hill coefficient of the glutamate concentrationresponse curves (Fig. 2, D 
and E).
Specificity against Other Sites. YM-298198 showed neither agonistic nor antagonistic activity on mGluR2, 3, 4a, 6, or 7b up to 10 M (Table 1) . YM-298198 showed no affinity for ionotropic glutamate receptors and glutamate transporters up to 10 M ( AMPA, ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; CGP39653, (E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid. (Fig. 6) . YM-298198 did not affect motor coordination assessed with Rotarod performance time in mice up to 30 mg/kg p.o., on the other hand, whereas haloperidol significantly reduced the Rotarod performance time at 3 mg/kg p.o. (Fig. 7) .
Discussion
The potency of YM-298198 (IC 50 of 16 Ϯ 5.8 nM) at glutamate-induced IP production inhibition is almost the same as or higher than existing mGluR1 antagonists such as CPCCOEt and R214127 (Lavreysen et al., 2003) , indicating that YM-298198 is a potent mGluR1 antagonist. YM-298198 decreased the maximal response to glutamate even at low concentrations, although previously reported allosteric antagonists CPCCOEt, BAY36-7602, and R214127 did so only at high concentrations (Hermans et al., 1998; Carroll et al., 2001) . The antagonist concentrations needed to effect a maximal response to glutamate are possibly dependent on the amount of expression of mGluR1 on the membranes used. That is to say, the maximum response was effected even by low concentrations of YM-298198 in our study, possibly due to the low level of expression of mGluR1 on mGluR1-NIH cells, i.e., the absence of spare receptors on the membrane. YM-298198 did not show agonist or antagonist activity at mGluRs2-7 up to 10 M, suggesting specificity to mGluR1 as opposed to other mGluR subtypes. The selectivity was also supported by the weak binding affinity for mGluR5, which has the highest homology to mGluR1 among mGluR subtypes. Furthermore, the selectivity against ionotropic gluta- Ͼ1,000,000 (RS)-AMPA Ͼ1,000,000 Kainate Ͼ1,000,000 NBQX Ͼ1,000,000 GYKI 52466 Ͼ1,000,000 NMDA Ͼ1,000,000 Glycine Ͼ1,000,000 (ϩ)-MK-801 Ͼ1,000,000
NBQX, 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline. conclusion that YM-298198 binds to the CPCCOEt (allosteric) site rather than the glutamate (agonist) site. YM-291898 showed an obvious antinociceptive effect in streptozotocin-induced hyperalgesic mice, indicating that YM-298198 is also highly active in in vivo models even with oral treatment. It has been reported that mutant mice lacking mGluR1 show an increase in the nociceptive threshold (Corsi et al., 1996) and that intrathecal administration of mGluR1 antisense oligonucleotides shows an analgesic effect in various animal pain models (Fundytus et al., 2001 (Fundytus et al., , 2002 Noda et al., 2003) . The analgesic activity of YM-298198 in the present study accords well with these previous findings. YM-298198 did not affect motor coordination assessed by the Rotarod test, although mGluR1 knockout mice reportedly showed ataxic behavior (Aiba et al., 1994) . It is possible that mGluRs are involved mainly in the development but not the maintenance of neuronal conditions related to motor coordination. In vivo studies with YM-298198 suggest that specific mGluR1 antagonists would be useful in the treatment of pain conditions.
In conclusion, YM-298198 is a newly synthesized, highaffinity, selective, and noncompetitive antagonist of mGluR1, and it will be a useful pharmacological tool due to its highly active properties in vitro and in vivo. Its radiolabeled form [ 3 H]YM-298198 will also be a valuable tool for future investigation of mGluR1.
